3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
45
Neoplasms
5
Colorectal Neoplasms
5
Neoplasm Metastasis
3
Adenocarcinoma
3
Resectable Pancreatic Cancer
2
Rectal Neoplasms
2
Pancreatic Cancer Metastatic
2
Carcinoma, Hepatocellular
2
Biliary Tract Neoplasms
2
Stomach Neoplasms
1
Pancreatic Ductal Adenocarcinoma (PDAC)
1
Pancreatic Cancer Non-resectable
1
Pancreatic Adenocarcinoma
1
Neoplasms, Basal Cell
1
Locally Advanced Pancreatic Adenocarcinoma
1
Localized Pancreatic Adenocarcinoma
1
Gastrointestinal Neoplasms
1
Gastroesophageal Adenocarcinoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Islet Cell
1
Carcinoma
1
Borderline Resectable Pancreatic Cancer
1
Interventions
Gemcitabine
11
pembrolizumab
10
Oxaliplatin
7
Nivolumab
7
Irinotecan
7
Fluorouracil
7
Capecitabine
7
durvalumab
6
Sorafenib
6
Leucovorin
6
Cyclophosphamide
6
Paclitaxel
5
Ipilimumab
5
tislelizumab
3
poly ICLC
3
lenvatinib
3
fludarabine
3
Sunitinib
3
Radiotherapy
3
Cisplatin
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
seocalcitol
2
selinexor
2
pemigatinib
2
futuximab
2
fludarabine phosphate
2
donafenib
2
cemiplimab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
folfirinox
×
Gastrointestinal
×
Clear all
NCT04990037
2023-06-29
CAPAFOUR
Cantargia AB
Phase 1
Completed
25 enrolled